Photo by clearcannabis from unsplash
There remains an unmet need for oral medications that are safe and efficacious for long‐term management of chronic inflammatory skin diseases (CISD). Inhibition of phosphodiesterase 4 (PDE4) can modulate a… Click to show full abstract
There remains an unmet need for oral medications that are safe and efficacious for long‐term management of chronic inflammatory skin diseases (CISD). Inhibition of phosphodiesterase 4 (PDE4) can modulate a broad range of pro‐inflammatory cytokines that play a major role in CISD pathogenesis. Orismilast is a second generation PDE4 inhibitor in clinical development for CISD treatment.
Keywords:
pharmacology;
pharmacology orismilast;
orismilast potent;
pde4;
pde4 inhibitor
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!